Infusion Magazine

BLOOD/BLOOD PRODUCT THERAPY

Andrews D. The expanding use of IVIG: Insights into its mechanism of action. 3001;7(7):28-32.

Barrell JM. IVIG: The next distribution battleground? 1999;6(3):35-41.

Barrell JM. Plasma-derived products: No relief in sight. 2001;7(7):34-5.

Barrell JM. Plasma therapies: How new indications, safety measures, and industry consolidation affect supply and demand. 2002;8(4):13-8.

Counce JB. Home IGIV under Medicare: Patients still waiting for meaningful coverage. 2005:11(2):12-20.

Cohen RJ. Home transfusion therapy: The time has come. 1995;1(6):44-45.

Kaplan LK. Lives distrupted: Coping with Bayer Direct. 1999;6(3):42-4.

Kaplan LK. Bayer Responds. 2000;6(4):30.

Kaplan LK. Bayer direct update: Patient advocacy groups speak out. 2000;6(7):12-4.

Lima HA. Von Willebrand disease: Diagnosis and treatment in the home care setting. 2006. 12(2):S1-S12.

McKinnon BT. Growth hormone: It's not just for kids. 1999;5(6):32-36.

McKinnon BK. Supply and demand. 1999;5(7):41-43.

Mendelsohn C and Riley P. IGIV fundamentals for home care and alternate site therapy. 2003;9(6):35-8.

Rizk M. Hemophilia and biotechnology: An update. 1999;5(6):23-26.

Siegel J. Guidelines for the safe administration of intravenous immune globulin in the home. 1995;1(10):40-48.

Siegel J. IGIV: Uses in autoimmune diseases. 2004.10(5):S1-S8.

Speidel K. Subcutaneous administration of immunoglobulin replacement therapy in the home care setting. 2006. 12(3):S1-S8.

Werner K. Exciting new IGIV research presented at the 5th international symposium of IGIV. 2004;10(1):33-7.

Zimay D and Erickson K. Pediatric patients with immune disorders: Utilization patterns and clinical outcomes. 1999;5(8):29-33.